Sign In
Last checked at 
7 Jun 2021 18:23
7 June 2021
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified on 4 June 2021 that Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust ("EBT"), have purchased ordinary shares ("Shares") on behalf of Susanne Munksted (PDMR), in respect of her initial purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.
As announced on 30 April 2021, under the SIP Scheme, the Company will match this purchase with a matched share award being the grant of a single one-off option over an equivalent number of Shares purchased by the employee, over the forthcoming period to July 2022 and subsequent 12 month periods thereafter, in the proportion of 2:1 for all purchases up to and including April 2022 and 1:1 for all purchases thereafter. The options will be formally granted in the future, expected to be within July, at an exercise price of nil.
Enquiries:
Diaceutics PLC |
|
Philip White, Chief Financial Officer | Via Alma PR |
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison |
|
Stewart Wallace |
|
Nick Adams |
|
|
|
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | diaceutics@almapr.co.uk |
Robyn Fisher |
|
Kieran Breheny |
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Susanne Munksted | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Managing Director and PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares to be matched by the future grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) |
| Share purchase: |
|
|
| |
| Price(s) | Volume(s) |
| ||||
129.00 p | 111 |
| |||||
Matching option award: Option over 222 Shares (exercise price: nil) to be awarded in July 2021 | |||||||
d. | Date of the transaction | Share purchase: 28 May 2021 (Company informed 4 June 2021) Option award: To be formally entered into in July 2021 | |||||
e. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Future option award: Off-Market | |||||
Follow the stocks
